BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1 AND Treatment
35 results:

  • 1. Discovery of ganoderic acid A (GAA) PROTACs as MDM2 protein degraders for the treatment of breast cancer.
    Li Y; Li G; Zuo C; Wang X; Han F; Jia Y; Shang H; Tian Y
    Eur J Med Chem; 2024 Apr; 270():116367. PubMed ID: 38581732
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. vhl suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation.
    Wang Z; Yan M; Ye L; Zhou Q; Duan Y; Jiang H; Wang L; Ouyang Y; Zhang H; Shen Y; Ji G; Chen X; Tian Q; Xiao L; Wu Q; Meng Y; Liu G; Ma L; Lei B; Lu Z; Xu D
    EMBO J; 2024 Mar; 43(6):931-955. PubMed ID: 38360997
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Fluorescence theranostic PROTACs for real-time visualization of ERα degradation.
    Wang X; Xin L; Deng X; Dong C; Hu G; Zhou HB
    Eur J Med Chem; 2024 Mar; 267():116184. PubMed ID: 38320426
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Design, synthesis, and evaluation of vhl-based EZH2 degraders for breast cancer.
    Xiao B; Shi Z; Liu J; Huang Q; Shu K; Liu F; Zhi C; Zhang D; Wu L; Yang S; Zeng X; Fan T; Liu Z; Jiang Y
    Bioorg Chem; 2024 Feb; 143():107078. PubMed ID: 38181661
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Glutathione-responsive PROTAC for targeted degradation of ERα in breast cancer cells.
    Zhou Z; Fan H; Yu D; Shi F; Li Q; Zhang Z; Wang X; Zhang X; Dong C; Sun H; Mi W
    Bioorg Med Chem; 2023 Dec; 96():117526. PubMed ID: 38008041
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.
    Lee K; Lee J; Choi J; Sim SH; Kim JE; Kim MH; Park YH; Kim JH; Koh SJ; Park KH; Kang MJ; Ahn MS; Lee KE; Kim HJ; Ahn HK; Kim HJ; Park KU; Park IH
    Sci Rep; 2023 Jun; 13(1):9928. PubMed ID: 37336919
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Genetic mutations in HER2-positive breast cancer: possible association with response to trastuzumab therapy.
    Zakaria NH; Hashad D; Saied MH; Hegazy N; Elkayal A; Tayae E
    Hum Genomics; 2023 May; 17(1):43. PubMed ID: 37202799
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. PIN1 and CDK1 cooperatively govern pvhl stability and suppressive functions.
    Chen J; Li M; Liu Y; Guan T; Yang X; Wen Y; Zhu Y; Xiao Z; Shen X; Zhang H; Tang H; Liu T
    Cell Death Differ; 2023 Apr; 30(4):1082-1095. PubMed ID: 36813923
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Targeted MDM2 Degradation Reveals a New Vulnerability for p53-Inactivated Triple-Negative breast cancer.
    Adams CM; Mitra R; Xiao Y; Michener P; Palazzo J; Chao A; Gour J; Cassel J; Salvino JM; Eischen CM
    Cancer Discov; 2023 May; 13(5):1210-1229. PubMed ID: 36734633
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. TET2 Suppresses vhl Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling.
    Zhang X; Li S; He J; Jin Y; Zhang R; Dong W; Lin M; Yang Y; Tian T; Zhou Y; Xu Y; Lei QY; Zhang J; Zhang Q; Xu Y; Lv L
    Cancer Res; 2022 Jun; 82(11):2097-2109. PubMed ID: 35176127
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.
    Terry S; Dalban C; Rioux-Leclercq N; Adam J; Meylan M; Buart S; Bougoüin A; Lespagnol A; Dugay F; Moreno IC; Lacroix G; Lorens JB; Gausdal G; Fridman WH; Mami-Chouaib F; Chaput N; Beuselinck B; Chabaud S; Barros-Monteiro J; Vano Y; Escudier B; Sautès-Fridman C; Albiges L; Chouaib S
    Clin Cancer Res; 2021 Dec; 27(24):6749-6760. PubMed ID: 34407968
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Time Trends in Receipt of Germline Genetic Testing and Results for Women Diagnosed With breast cancer or Ovarian cancer, 2012-2019.
    Kurian AW; Ward KC; Abrahamse P; Bondarenko I; Hamilton AS; Deapen D; Morrow M; Berek JS; Hofer TP; Katz SJ
    J Clin Oncol; 2021 May; 39(15):1631-1640. PubMed ID: 33560870
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Caveolin-1 inhibits breast cancer stem cells via c-Myc-mediated metabolic reprogramming.
    Wang S; Wang N; Zheng Y; Yang B; Liu P; Zhang F; Li M; Song J; Chang X; Wang Z
    Cell Death Dis; 2020 Jun; 11(6):450. PubMed ID: 32528105
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Polymorphisms in GSTT1 and GSTM1 genes as possible risk factors for susceptibility to breast cancer development and their influence in chemotherapy response: a systematic review.
    Pacholak LM; Amarante MK; Guembarovski RL; Watanabe MAE; Panis C
    Mol Biol Rep; 2020 Jul; 47(7):5495-5501. PubMed ID: 32494978
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Selective CDK6 degradation mediated by cereblon, vhl, and novel IAP-recruiting PROTACs.
    Anderson NA; Cryan J; Ahmed A; Dai H; McGonagle GA; Rozier C; Benowitz AB
    Bioorg Med Chem Lett; 2020 May; 30(9):127106. PubMed ID: 32184044
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Next-generation sequencing identifies recurrent copy number variations in invasive breast carcinomas from Ghana.
    Anwar T; Rufail ML; Djomehri SI; Gonzalez ME; Lazo de la Vega L; Tomlins SA; Newman LA; Kleer CG
    Mod Pathol; 2020 Aug; 33(8):1537-1545. PubMed ID: 32152520
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Regulation of KLF4 by posttranslational modification circuitry in endocrine resistance.
    Zhou Z; Song X; Chi JJ; Gius DR; Huang Y; Cristofanilli M; Wan Y
    Cell Signal; 2020 Jun; 70():109574. PubMed ID: 32084531
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Design and Characterization of SGK3-PROTAC1, an Isoform Specific SGK3 Kinase PROTAC Degrader.
    Tovell H; Testa A; Zhou H; Shpiro N; Crafter C; Ciulli A; Alessi DR
    ACS Chem Biol; 2019 Sep; 14(9):2024-2034. PubMed ID: 31461270
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in breast cancer Patients: Potential Implication of Genomic Alterations of Discordance.
    Kim HK; Park KH; Kim Y; Park SE; Lee HS; Lim SW; Cho JH; Kim JY; Lee JE; Ahn JS; Im YH; Yu JH; Park YH
    Cancer Res Treat; 2019 Apr; 51(2):737-747. PubMed ID: 30189722
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models.
    Reguera-Nuñez E; Man S; Xu P; Kerbel RS
    Angiogenesis; 2018 Nov; 21(4):793-804. PubMed ID: 29786782
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.